Virchows Archiv A

, Volume 420, Issue 2, pp 139–148 | Cite as

Amyloid enhancing factor activity is associated with ubiquitin

  • Kamel Alizadeh-Khiavi
  • Josée Normand
  • Soula Chronopoulos
  • Ambereen Ali
  • Zafer Ali-Khan
Original Articles

Summary

Crude amyloid enhancing factor (AEF) drastically reduces the pre-amyloid phase on passive transfer and induces amyloid deposition in the recipient mice in 48–120h. We attempted to purify AEF from murine amyloidotic liver and spleen extracts by using gel filtration, preparative sodium dodecyl sulphate-polyacrylamide gel electrophoresis and ion exchange chromatography and isolated a 5.5. kDa peptide. In the mouse bioassay, this peptide induced accelerated splenic AA deposition in a dose-dependent manner. Based on structural, electrophoretic and immunochemical criteria the peptide was identified as ubiquitin. A polyclonal rabbit anti-bovine ubiquitin IgG antibody (RABU) abolished the in vivo AEF activity of crude murine AEF in a dose-dependent manner. Monomeric ubiquitin and its large molecular weight adducts were isolated from crude AEF using cyanogen bromide-activated sepharose conjugated to RABU and size exclusion chromatography methods. These were assayed and were found to possess AEF activity. Furthermore, increased levels of ubiquitin, a phenomenon similar to that of AEF, were detected by immunocytochemistry in mouse peritoneal leucocytes prior to and during amyloid deposition. Since AEF shares a number of biological and functional properties with ubiquitin, we suggest a possible role of ubiquitin as an AEF, and that serum amyloid protein A and ubiquitin, the two reactants generated during inflammatory stress conditions, may converge to induce AA amyloid deposition

Key words

Amyloid enhancing factor Ubiquitin Amino acid sequencing anti-ubiquitin antibody Immunocytochemistry 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abankwa GA, Ali-Khan Z (1988) Alveolar hydatid cyst induced amyloid enhancing factor (AEF): physicochemical properties and abolition of AEF activity by serine protease inhibitors. Br J Exp Pathol 69:133–148PubMedGoogle Scholar
  2. Abraham CR, Selkoe DJ, Potter H (1988) Immunochemical identification of the serine protease inhibitor α1-antichymotrypsin in the brain deposits of Alzheimer's disease. Cell 52:487–501CrossRefPubMedGoogle Scholar
  3. Ali-Khan Z, Quirion R, Robittaile Y, Alizadeh-Khiavi K, Du T (1988) Evidence for increased amyloid enhancing factor activity in Alzheimer brain extract. Acta Neuropathol (Berl) 77:82–90Google Scholar
  4. Alizadeh-Khiavi K, Ali-Khan Z (1988) Biochemical nature and cellular origin of amyloid enhancing factor (AEF) as determined by anti-AEF antibody. Br J Exp Pathol 69:605–619PubMedGoogle Scholar
  5. Alizadeh-Khiavi K, Ali-Khan Z (1990) Possible role of amyloid enhancing factor (ubiquitin) in Alzheimer's disease and reactive amyloidosis. Neurobiol Aging 11:302Google Scholar
  6. Alizadeh-Khiavi K, Normand J, Chronopoulos S, Ali-Khan Z (1991) Alzheimer brain derived ubiqutin has amyloid enhancing factor activity: behavior of ubiquitin during accelerated amyloidogenesis. Acta Neuropathol (Berl) 81:280–286Google Scholar
  7. Axelrad MA, Kisilevsky R (1980) Biological characterizations of amyloid enhancing factor. In: Glenner GG, Pinhoe Costa P, Falcao de Frietas A (eds) Amyloid and amyloidosis. Excerpta Medica, Amsterdam, pp 527–533Google Scholar
  8. Axelrad MA, Kisilevsky R, Willmar J, Cohen SJ, Skinner M (1982) Further characterzation of amyloid-enhancing factor. Lab Invest 47:139–146PubMedGoogle Scholar
  9. Chronopoulos S, Alizadeh-Khiavi K, Normand J, Ali-Khan Z (1991a) Binding of ubiquitin to experimentally induced murine AA amyloid. J Pathol 163:199–203CrossRefPubMedGoogle Scholar
  10. Chronopoulos S, Lembo P, Alizadeh-Khiavi K, Normand J, Ali-Khan Z (1991 b) Ubiquitin: its potential significance in murine AA amyloidosis. J Pathol (in press)Google Scholar
  11. Cowan DF, Johnson WC (1970) Amyloidosis in the white Peking Duck. I. Relation to social environmental stress. Lab Invest 23:551–555PubMedGoogle Scholar
  12. Du T, Ali-Khan Z (1990) Pathogenesis of secondary amyloidosis in an alveolar hydatid cyst-mouse model: histopathology and immuno/enzyme-histochemical analysis of splenic marginal zone cells during amyloidogenesis. J Exp Pathol 71:313–316Google Scholar
  13. Fried VA, Smith HT, Hildebrandt E, Weiner K (1987) Ubiquitin has intrinsic proteolytic activity: implications for cellular regulation. Proc Natl Sci USA 84:3685–3698Google Scholar
  14. Fuks A, Zucker-Franklin D (1985) Impaired Kupffer cell function precedes development of secondary amyloidosis. J Exp Med 161:1013–1026CrossRefPubMedGoogle Scholar
  15. Gervais F, Herbert L, Skamena E (1988) Amyloid enhancing factor: production and response in amyloidosis-susceptible and resistant mouse strains. J Leukoc Biol 43:311–316PubMedGoogle Scholar
  16. Glenner GG (1980) Amyloid deposits and amyloidosis. The β-fibrilloses. N Engl J Med 302:1283–1292PubMedGoogle Scholar
  17. Grundke-Iqbal I, Iqbal K, George L, Tung Y, Kim KS, Wisnieski HM (1989) Amyloid protein and neurofibrillary tangles coexist in the same neuron in Alzheimer disease. Proc Natl Acad Sci USA 86:2853–2857PubMedGoogle Scholar
  18. Hall CE, Cross E, Hall O (1960) Amyloidosis and other pathologic changes in mice exposed to chronic stress. Tex Rep Biol Med 18:205–213PubMedGoogle Scholar
  19. Hardt F, Hellung-Larsen P (1972) Transfer amyloidosis: studies on the nature of the amyloid inducing factor in a murine transfer system. Clin Exp Immunol 10:487–492PubMedGoogle Scholar
  20. Hass AL, Bright PM (1985) The immunochemical detection and quantitation of intracellular ubiquitin-protein conjugates. J Biol Chem 260:12464–12473Google Scholar
  21. Hoffman JS, Ericsson LH, Eriksen N, Walsh KA, Benditt EP (1984) Murine tissue amyloid protein AA: NH2-terminal sequence identity with only one of two serum amyloid protein (apoSAA) gene products. J Exp Med 159:641–645CrossRefPubMedGoogle Scholar
  22. Hol PR, Van Andel ACJ, Van Enderen AM, Draayer J, Gruys E (1985) Amyloid enhancing factor in hamster. Br J Exp Pathol 66:689–697PubMedGoogle Scholar
  23. Ivy GO, Kitani K, Ihara Y (1989) Anomalous accumulation of τ and ubiquitin immunoreactivities in rat brain caused by protease inhibition and by normal aging: a clue to PHF pathogenesis. Brain Res 498:360–365CrossRefPubMedGoogle Scholar
  24. Kisilevsky R (1983) Amyloidosis: a familial problem in the light of current pathogenetic developments. Lab Invest 49:381–390PubMedGoogle Scholar
  25. Kisilevsky R, Axelrad M, Corbett W, Brunet S, Scott S (1977) The role of inflammatory cells in the pathogenesis of amyloidosis. Lab Invest 37:544–553PubMedGoogle Scholar
  26. Kula RW, Engel WK, Line BR (1977) Scanning for soft-tissue amyloid. Lancet I:92–93Google Scholar
  27. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685CrossRefPubMedGoogle Scholar
  28. Matsumoto H, Taniguchi N, Deutsch HF (1984) Isolation characterization, and esterase and CO hydration activities of ubiquitin from bovine erythrocytes. Arch Biochem Biophys 234:426–433CrossRefPubMedGoogle Scholar
  29. Mayer JR, Arnold J, Laszlo L, Landon M, Lowe J (1991) Ubiquitin in health and disease. Biochem Biophys Acta 1089:141–157PubMedGoogle Scholar
  30. McCubbin WD, Kay CM, Narindrasorasak S, Kisilevsky R (1988) Circular-dichroism studies on two murine serum amyloid A proteins. Biochem J 256:775–783PubMedGoogle Scholar
  31. Meek RL, Eriksen N, Benditt EP (1989) Serum amyloid A in the mouse: sites of uptake and mRNA expression. Am J Pathol 135:411–419PubMedGoogle Scholar
  32. Niewold THA, Hol PR, Van Andel ACJ, Lutz ETG, Gruys E (1987) Enhancement of amyloid induction by amyloid fibril fragments in hamsters. Lab Invest 56:544–549PubMedGoogle Scholar
  33. Niewold THA, Gruys E, Kisilvesky R, Shirahama TS (1991) Fibril amyloid enhancing factor (FACF) — accelerated amyloidosis in the hamster is not dependent on serine esterase activity and mononuclear phagocytosis. Scand J Immunol 34:101–107PubMedGoogle Scholar
  34. Page DL, Glenner GG (1972) Special interaction of wounding in the genesis of ‘spontaneous’ murine amyloidosis. Am J Pathol 67:555–567PubMedGoogle Scholar
  35. Perlmutter DH (1988) Distinct meidators and mechanisms regulate human acute phase gene expression. In: Perdue ML, Feramisco JH, Lindquist S (eds) Stress induced proteins. Liss, New York, pp 257–274Google Scholar
  36. Rechsteiner M (1989) Ubiquitin-mediated pathways for intracellular proteolysis. Annu Rev Cell Biol 3:1–30Google Scholar
  37. Rosenthal CJ, Sullivan L (1979) Serum amyloid A: evidence for its origin in polymorphonuclear leukocytes. J Clin Invest 62:1181–1186Google Scholar
  38. Shirahama T, Miura K, Ju S-T, Kisilevsky R, Gruys E, Cohen AS (1990a) Amyloid enhancing factor-loaded macrophages in amyloid fibril formation. Lab Invest 62:61–68PubMedGoogle Scholar
  39. Shirahama T, Abraham CR, Ju S-T, Miurak K, Cohen AS, Kisilevsky R, Grys E (1990b) Isolation of a 16 KD fraction with extremely high AEF activity. In: Natvig JB et al. (eds) Amyloid and amyloidosis. Kluwer, London, pp 288–291Google Scholar
  40. Silverman SL, Cathcart ES, Skinner M, Cohen AS, Burnett L (1980) A pathogenetic role for polymorphonuclear leukocytes in the synthesis and degradation of SAA protein. In: Glenner GG et al. (eds) Amyloid and amyloidosis. Excerpta Medica, Amsterdam, pp 420–425Google Scholar
  41. Sipe JD, McAdam KPWJ, Uchino F (1978) Biochemical evidence for the biphasic development of experimental amyloidosis. Lab Invest 38:110–114PubMedGoogle Scholar
  42. Skinner M, Stone P, Shirahama T, Connors LH, Calore J, Cohen AS (1986) The association of an elastase with amyloid fibrils. Proc Soc Exp Biol Med 181:211–214PubMedGoogle Scholar
  43. Snow A, Kisilevsky R, Stephens C, Anastassiades T (1987) Characterization of serum and splenic glycosaminoglycans during rapid AA amyloid induction. Qualitative and quantitative analysis. Lab Invest 56:665–675PubMedGoogle Scholar
  44. Stone MJ (1990) Amyloidosis: a final common pathway for protein deposition in tissues. Blood 75:531–545PubMedGoogle Scholar
  45. Turnell W, Sarra R, Glover ID, Baum JO (1986) Secondary structure prediction of human SAA1, Presumptive identification of calcium and lipid binding sites. Mol Biol Med 3:387–407PubMedGoogle Scholar
  46. Varga J, Flinn MSM, Shirahama T, Rogers OG, Cohen AS (1986) The induction of accelerated murine amyloid with human splenic extract. Virchows Arch [B] 51:177–185Google Scholar
  47. Yamamoto KI, Migita S (1985) Complete primary structures of two major murine serum amyloid A proteins deduced from cDNA sequences. Proc Natl Acad Sci USA 82:2915–2919PubMedGoogle Scholar
  48. Yokota T, Ishihara T, Kawano H, Takahashi M, Fujinaga Y, Uchino F (1989) Amyloid enhancing factor (AEF) in the aging mouse. Virchows Arch [A] 414:511–514Google Scholar
  49. Zuckerman SA, Suprenant YM (1986) Simplified micro ELISA for the quantitation of murine serum amyloid A protein. Immunol Methods 92:37–43CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • Kamel Alizadeh-Khiavi
    • 1
  • Josée Normand
    • 1
  • Soula Chronopoulos
    • 1
  • Ambereen Ali
    • 1
  • Zafer Ali-Khan
    • 1
  1. 1.Department of Microbiology and ImmunologyMcGill UniversityMontrealCanada

Personalised recommendations